Madison, WI, United States of America

Erich Altenhofer

USPTO Granted Patents = 4 

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
4 patents (USPTO):

Title: Erich Altenhofer: Innovator in RNA Interference Technology

Introduction

Erich Altenhofer is a prominent inventor based in Madison, WI (US), known for his significant contributions to the field of RNA interference (RNAi) technology. With a total of four patents to his name, Altenhofer has made strides in developing innovative solutions for gene expression inhibition.

Latest Patents

Altenhofer's latest patents include groundbreaking work on RNAi agents designed to inhibit the expression of HIF-2 alpha (EPAS1) gene. These agents are particularly relevant for treating clear cell renal cell carcinoma (ccRCC). The patents also describe pharmaceutical compositions that incorporate HIF-2 alpha RNAi agents, which may be linked to targeting ligands and pharmacokinetic enhancers to improve delivery to specific cells and tissues. Another notable patent focuses on trialkyne linking agents that enhance the attachment of targeting groups or delivery agents to oligonucleotides, improving their stability and biological activity.

Career Highlights

Altenhofer is currently employed at Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His work has the potential to revolutionize treatment options for various diseases by providing targeted therapies that inhibit harmful gene expressions.

Collaborations

Throughout his career, Altenhofer has collaborated with notable colleagues, including Zhen Li and Tao Pei, contributing to the advancement of innovative solutions in the field of biotechnology.

Conclusion

Erich Altenhofer's contributions to RNA interference technology exemplify the impact of innovative thinking in the medical field. His patents and ongoing research at Arrowhead Pharmaceuticals, Inc. highlight the importance of targeted therapies in treating complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…